Bone Biologics - Warrants (13/10/2026) EBIT

The latest EBIT for BBLGW is $-3M as of June 2026. That compares with $-4.3M in the prior-year period — up 31.1% year over year. That is above the sector sector average of $-26M. Investors often review this figure alongside Bone Biologics - Warrants (13/10/2026)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BBLGW's EBIT moved from $-4.3M to $-3M — a 31.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bone Biologics - Warrants (13/10/2026)'s operating scale or balance-sheet position.

Against its sector companies, BBLGW currently prints $-3M for EBIT, while the sector average sits near $-26M. That is roughly 88.6% above the sector mean. Large gaps often invite a closer look at Bone Biologics - Warrants (13/10/2026)'s growth, margins, and balance sheet.

A EBIT figure of $-3M for BBLGW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-26M. Explore the charts below for those layers of context.

After noting BBLGW's EBIT ($-3M), review year-over-year change from $-4.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.